This reflects the importance of this drug in the treatment of locally advanced breast cancer, as well as the presence of a smaller number of participants with HER-2-positive tumors (33.4% in our study), in which current evidence shows that anthracycline is not used in its respective treatment [32]. The gene discussed is ERBB2; the disease is breast carcinoma.